Capital Nasdaq Biotechnology Etf Current Valuation
| 00678 Etf | TWD 28.74 0.64 2.18% |
Valuation analysis of Capital Nasdaq Biote helps investors to measure Capital Nasdaq's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Capital Nasdaq's price fluctuation is very steady at this time. Calculation of the real value of Capital Nasdaq Biote is based on 3 months time horizon. Increasing Capital Nasdaq's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Capital Nasdaq's intrinsic value may or may not be the same as its current market price of 28.74, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 28.74 | Real 28.97 | Hype 28.74 | Naive 28.71 |
The intrinsic value of Capital Nasdaq's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Capital Nasdaq's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Capital Nasdaq Biotechnology helps investors to forecast how Capital etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Capital Nasdaq more accurately as focusing exclusively on Capital Nasdaq's fundamentals will not take into account other important factors: Capital Nasdaq Biotechnology ETF Current Valuation Analysis
Capital Nasdaq's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Capital Nasdaq Biotechnology has a Current Valuation of 0.0. This indicator is about the same for the Capital Investment Trust Co., Ltd average (which is currently at 0.0) family and about the same as Current Valuation (which currently averages 0.0) category. This indicator is about the same for all Taiwan etfs average (which is currently at 0.0).
Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Fund Asset Allocation for Capital Nasdaq
The fund consists of 98.58% investments in stocks, with the rest of investments allocated between various types of exotic instruments.Asset allocation divides Capital Nasdaq's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Capital Fundamentals
| Total Asset | 178.4 M | |||
| One Year Return | 27.30 % | |||
| Three Year Return | 8.82 % | |||
| Net Asset | 178.4 M | |||
| Equity Positions Weight | 98.58 % |
About Capital Nasdaq Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Capital Nasdaq Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capital Nasdaq using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capital Nasdaq Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Capital Etf
Capital Nasdaq financial ratios help investors to determine whether Capital Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Capital with respect to the benefits of owning Capital Nasdaq security.